Abstract

This disclosure describes a fully integrated platform that non-invasively delivers a red-shifted opsin gene via focused ultrasound (FUS) and microbubbles, augments glymphatic clearance using a 16-element phased array in vortex mode generating rotating acoustic streaming, co-stimulates neural circuits optogenetically at 40 Hz synchronized to NREM slow-wave onset, and closes the loop using a five-channel monitoring system (four real-time hemodynamic surrogates — fUSi, thermal, acoustic backscatter, optical reflectance — fused into a clearance index, plus one direct ISF solute measurement via chronic cerebral microdialysis validated at 6-hour intervals) to dynamically adjust stimulation amplitude during the brain's own clearance window. Three engineering subsystems — a vortex-guided optical conduit (VGOC) for thermal management, an interstitial fluidic wash loop (IFWL) for chronic perfusion, and a thermoacoustic stabilization ring (TASR) for thermal drift compensation — address the primary translational barriers for chronic optogenetic stimulation.

The system operates as a tidal amplifier: it does not override the brain's endogenous glymphatic rhythm (norepinephrine-driven slow vasomotion during NREM sleep). It detects that rhythm via single-channel EEG, activates only during the clearance window when perivascular spaces are already dilated, and adds acoustic and optical force to an already-open door. The feedback controller adjusts amplitude (not timing) based on the fused clearance measurement. The feedback controller is gated: it is disabled until the surrogate passes three-tier validation (bench, tracer, and endpoint correlation), ensuring that control authority is only granted to a signal that has demonstrated biological validity.

The platform is designed for bench-scale construction using commercially available components and standard core-facility resources. A complete testing protocol (bench → in-vivo) is provided with six experimental groups enabling disentanglement of individual modality contributions and synergy assessment. The system is intended for use in rodent models of Alzheimer's disease (5xFAD) and wild-type mice for glymphatic flow characterization.

Novelty statement: While individual components (FUS-mediated BBB opening, acoustic streaming enhancement of glymphatic flow, 40 Hz optogenetic stimulation, fUSi imaging, phased-array vortex beams) have been demonstrated in isolation, no published system integrates a phased-array vortex-mode acoustic pump, sleep-phase-locked optogenetic co-stimulation, NIR thermo-elastic expansion, and multi-sensor fused closed-loop clearance feedback with hierarchical surrogate validation into a single platform. The VGOC, IFWL, TASR, and chronic microdialysis validation channel are also novel additions not present in any published optogenetic or FUS-based platform.

Relationship to prior disclosures: This document is the research-grade, closed-loop, sleep-synchronized evolution of the author's GCI-128 Neuro-Vortex Protocol v3.1, the clearance-pathway framework in GCI #274 and CNG-Loop v1.0, the phased-array vortex physics in AFMU-1 and UAAP-2.0, the multi-sensor fusion architecture in FDMS-1.0, and the sleep-synchronization principle in ACCS v4.0.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS